ANTIVIRAL TREATMENT OF HEPATITIS C IN SERBIAN PRISON SETTING: MEDICAL TREATMENT OUTCOMES AND PATIENTS' ADHERENCE.
2016
Introduction. Seroprevlence of chronic hepatitis C viral infection in
correctional facilities ranges from 16% to 49%. However, there are only very
limited data available on the course of hepatitis C viral infection and
outcomes of treatment with pegylated interferon plus ribavirin in
correctional settings. The aim of this study was to assess the feasibility
and effectiveness of use of pegylated interferon plus ribavirin treatment in
the Serbian correctional setting. Material and Methods. The study sample
consisted of the patients with hepatitis C hospitalized in the Special
Hospital for Prisoners in Belgrade (Serbia) during 2007-2013. Health
authorities approved treatment for 32 patients out of 76 treatment-naive
patients referred to this institution. The patients (N=32) received 180 mcg
pegylated interferon alfa-2a once a week plus oral ribavirin in dosage of
800mg or 1000/1200 mg/day for 24 or 48-week treatment. All patients who
completed therapy were assessed at the end of an additional 24-week
treatment-free period for a sustained virological response. Results.
Sustained virological response was achieved in 53.8% of hepatitis C viral
infection genotype 1 patients and in 73.3% and 66.6% of patients with
hepatitis C viral infection genotype 3 and 4, respectively. One patient with
mixed genotype (1, 2) did not achieve sustained virological response. The
overall safety profile of the treatment regimen was very good. The incidence
of influenza-like symptoms and depression were low. A serious adverse event
was recorded only in 6.4% of patients. Conclusion. The results showed that
pegylated interferon alfa-2a plus ribavirin given once a week was well
tolerated among prisoners and the regimen had the same adherence and
effectiveness as in general population.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI